ABCG47 Antibody

What is CD47 and why is it a target for cancer immunotherapy?

CD47 is a cell surface receptor expressed on healthy cells and often overexpressed on cancer cells. It functions as a "don't eat me" signal by interacting with Signal Regulatory Protein Alpha (SIRPα), an inhibitory immunoreceptor expressed on myeloid cells including macrophages, neutrophils, and subsets of dendritic cells . This interaction inhibits phagocytosis, allowing cancer cells to evade immune surveillance.

CD47 has emerged as an essential checkpoint for cancer immunosurveillance. In several preclinical studies, therapeutic antibodies that block the interaction between CD47 and SIRPα promote effective antitumor responses by enabling elimination of both hematologic and solid tumor cells by phagocytes, enhancing cross-presentation to CD8+ T cells, and triggering adaptive immune responses .

How do anti-CD47 antibodies promote antitumor immunity?

Anti-CD47 antibodies promote antitumor immunity through multiple mechanisms:

• Blockade of CD47-SIRPα interaction: By preventing CD47 on tumor cells from binding to SIRPα on macrophages, these antibodies remove the inhibitory "don't eat me" signal, enhancing phagocytosis of cancer cells .

• Enhanced tumor infiltration by macrophages: Studies show that anti-CD47 antibodies, particularly those with enhanced FcγR binding, increase the percentage of tumor-infiltrating macrophages and monocytes .

• Improved cross-presentation: CD47 blockade promotes adaptive immune responses by increasing cross-presentation of tumor antigens by dendritic cells to CD8+ T cells .

• Regulatory T cell depletion: Anti-CD47 antibodies with enhanced FcγR binding can selectively deplete regulatory T cells that express high levels of CD47, reducing immunosuppression in the tumor microenvironment .

• Long-term antitumor immunity: Treatment with anti-CD47 antibodies facilitates development of long-term CD8+ tumor-specific immunity that can protect against tumor rechallenge .

What are the challenges in developing effective anti-CD47 therapeutic antibodies?

Several significant challenges exist in developing effective anti-CD47 therapeutic antibodies:

• On-target off-tumor toxicity: CD47 is ubiquitously expressed on normal cells, including red blood cells and platelets. This can lead to anemia and thrombocytopenia when using anti-CD47 antibodies, limiting the therapeutic window .

• Limited clinical benefit as monotherapy: Despite promising preclinical results, anti-CD47 antibodies have shown limited clinical benefit as monotherapy in various malignancies, suggesting that CD47 blockade alone might be insufficient for effective tumor control .

• FcγR engagement optimization: Finding the optimal Fc domain configuration is challenging. Antibodies with weak or null engagement to FcγRs (hIgG4, hIgG2, or inert Fc region) show better tolerability but limited clinical benefit as monotherapy. Conversely, antibodies with competent binding to FcγRs (hIgG1 format) show higher therapeutic activity but greater toxicity .

• Translational models: Traditional preclinical models often fail to recapitulate the on-target off-tumor toxicity and therapeutic activity observed in patients, making it difficult to predict clinical outcomes .

What is the role of Fc-FcγR interactions in anti-CD47 antibody efficacy?

Fc-FcγR interactions play a critical role in the efficacy of anti-CD47 antibodies beyond simply blocking the CD47-SIRPα interaction:

• Enhanced therapeutic activity: Anti-CD47 antibodies with Fc domains engineered for increased binding to activating FcγRs (like mouse IgG2a or engineered human IgG1) demonstrate significantly greater antitumor activity compared to variants with reduced FcγR binding .

• Macrophage recruitment and activation: Engagement of activating FcγRs during treatment with anti-CD47 antibodies correlates with increased tumor infiltration by macrophages and enhanced phagocytic activity. This is evidenced by significant increases in CD11b+F4/80+ macrophages and CD11b+Ly6C+ monocytes in the tumor microenvironment .

• Regulatory T cell depletion: Anti-CD47 antibodies with Fc domains that engage activating FcγRs selectively deplete regulatory T cells (Tregs) that express high levels of CD47, reducing immunosuppression within the tumor microenvironment .

• Enhanced adaptive immunity: Fc-optimized anti-CD47 antibodies promote increased tumor-specific CD8+ T cell responses and long-term antitumor immunity, suggesting that FcγR engagement bridges innate and adaptive immune responses .

Research indicates that both mechanisms - CD47/SIRPα blockade and FcγR engagement - are necessary for optimal in vivo antitumor activity .

How do different Fc variants of anti-CD47 antibodies affect their therapeutic activity?

Different Fc variants of anti-CD47 antibodies significantly impact their therapeutic activity through varied engagement with FcγRs:

• Mouse IgG2a Fc variant: In murine models, anti-CD47 antibodies with mIgG2a Fc domains demonstrate superior antitumor activity compared to other isotypes. This superiority is observed in multiple tumor models, including B16 melanoma and MC38 colon cancer models .

• Mouse IgG1 D265A variant: This Fc-silent variant, which has minimal binding to all FcγRs, shows significantly reduced antitumor activity despite retaining CD47-SIRPα blockade capabilities, highlighting the importance of FcγR engagement .

• Human IgG1 variants: Anti-CD47 antibodies with human IgG1 Fc domains show the highest levels of therapeutic activity as monotherapy in clinical settings but are administered at low concentrations due to on-target off-tumor toxicity concerns .

• Human IgG4 and IgG2 variants: These isotypes with weak FcγR engagement show better tolerability but limited clinical benefit as monotherapy. They demonstrate benefit primarily in combination with other antitumor antibodies that engage FcγRs .

In combination therapy settings, particularly with tumor-targeting antibodies or immune checkpoint inhibitors, anti-CD47 antibodies with enhanced FcγR binding demonstrate significantly greater efficacy than other Fc variants .

What experimental models are most appropriate for studying anti-CD47 antibody activities?

The appropriate experimental models for studying anti-CD47 antibody activities should recapitulate both the therapeutic effects and potential toxicities observed in clinical settings:

• Humanized mouse models: Mice humanized for CD47, SIRPα, and FcγRs provide significant advantages over traditional models. These models are generated through CRISPR/Cas9 gene-editing where:

  • Human extracellular domains of CD47 and SIRPα replace their murine counterparts

  • Mouse FcγR genes are deleted and human FcγRs are expressed as transgenes

  • These models maintain the human cell-type specific expression profile of CD47, SIRPα, and FcγRs

• Species-matched tumor models: Using cancer cell lines in which murine CD47 is replaced with human CD47 (like MC38-hCD47 KI, B16-hCD47 KI) allows for testing human-specific anti-CD47 antibodies in immunocompetent settings .

• Metastatic models: Lung metastasis models (like B16 melanoma) have proven valuable for assessing the systemic antitumor effects of anti-CD47 antibodies .

• Subcutaneous tumor models: These are useful for evaluating combination therapies, as some anti-CD47 antibodies may not show efficacy as monotherapy in these models .

The fully humanized models (for CD47, SIRPα, and FcγRs) can recapitulate toxicities observed clinically, such as anemia and thrombocytopenia, making them valuable for translational research .

How does CD47 expression differ across various tumor-infiltrating immune cell populations?

CD47 expression varies significantly across different tumor-infiltrating immune cell populations, with important implications for anti-CD47 therapy:

• Regulatory T cells (Tregs): CD4+FOXP3+ regulatory T cells exhibit significantly higher expression of CD47 compared to CD4+FOXP3- conventional T cells or CD8+ T cells in the tumor microenvironment. This differential expression makes Tregs particularly susceptible to depletion by Fc-optimized anti-CD47 antibodies .

• Conventional T cells: Both CD4+FOXP3- T cells and CD8+ T cells express CD47, but at lower levels compared to Tregs. This differential expression may explain why Fc-optimized anti-CD47 antibodies preferentially deplete Tregs over other T cell populations .

• Myeloid cells: CD11b+ myeloid cells express CD47, though typically at lower levels than Tregs. Additionally, these cells express SIRPα, the receptor for CD47 .

• Tumor cells: Many cancer cells overexpress CD47 as a mechanism to evade immune surveillance, though expression levels can vary across different cancer types and even within the same tumor .

This differential expression pattern has therapeutic implications:

• The higher expression of CD47 on Tregs contributes to the mechanism by which Fc-optimized anti-CD47 antibodies reduce immunosuppression in the tumor microenvironment

• The preferential depletion of Tregs helps shift the balance toward effector T cell responses

What are the advantages of bispecific antibodies targeting CD47 and other immune checkpoints?

Bispecific antibodies targeting CD47 and other immune checkpoints offer several advantages over single-targeting agents:

• Wider therapeutic window: By simultaneously targeting CD47 and another immune checkpoint (like PD-1), bispecific antibodies can potentially widen the therapeutic window, providing improved efficacy and safety compared to monotherapies .

• Reduced binding affinity for CD47: Some bispecific antibodies, like HX009 (PD-1 x CD47), are designed with intentionally reduced CD47-binding affinity. This approach may help mitigate on-target off-tumor toxicities while maintaining efficacy through the synergistic effects of dual targeting .

• Synergistic targeting of innate and adaptive immunity: By targeting CD47 (primarily affecting innate immunity) and checkpoints like PD-1 (primarily affecting adaptive immunity), bispecific antibodies can simultaneously modulate multiple arms of the immune system .

• Novel molecular structures: Bispecific antibodies can utilize innovative designs, such as grafting the extracellular domain of SIRPα onto an anti-PD-1 antibody (as with HX009), resulting in IgG4-based "2 × 2" symmetric structures with unique functional properties .

• Improved tumor selectivity: Dual targeting may enhance tumor selectivity by requiring binding to both targets for maximal activity, potentially reducing off-tumor effects .

What mechanisms contribute to the limited clinical benefit observed with anti-CD47 antibodies as monotherapy?

Several mechanisms contribute to the limited clinical benefit observed with anti-CD47 antibodies as monotherapy:

• Insufficient FcγR engagement: Anti-CD47 antibodies with weak or null engagement to FcγRs (hIgG4, hIgG2, or inert Fc regions) demonstrate limited clinical benefit when administered as monotherapy. Research indicates that optimal in vivo antitumor activity requires both blockade of the CD47-SIRPα interaction and engagement of activating FcγRs .

• Dose-limiting toxicities: Antibodies with competent binding to FcγRs (hIgG1 format) show higher therapeutic activity but often require low dosing due to on-target off-tumor toxicity, limiting their efficacy. These toxicities include transient depletion of normal CD47-expressing cells such as red blood cells and platelets .

• Incomplete blockade of "don't eat me" signals: CD47 blockade alone might be insufficient to overcome multiple immune evasion mechanisms employed by cancer cells. Other "don't eat me" signals may compensate for CD47 blockade .

• Immunosuppressive tumor microenvironment: Even with effective CD47 blockade, other immunosuppressive mechanisms in the tumor microenvironment may limit the efficacy of anti-CD47 monotherapy .

• Limited tumor infiltration: Without engagement of activating FcγRs, some anti-CD47 antibodies fail to significantly increase tumor-infiltrating macrophages and other immune cells necessary for effective antitumor responses .

These limitations explain why anti-CD47 antibodies often show greater benefit in combination with other antitumor antibodies that engage FcγRs, such as Rituximab or Trastuzumab, or with immune checkpoint inhibitors .

How can the therapeutic index of anti-CD47 antibodies be optimized?

Optimizing the therapeutic index of anti-CD47 antibodies involves several strategies to maximize efficacy while minimizing toxicity:

• Fc domain engineering:

  • Developing Fc variants with preferential binding to activating FcγRs (like mIgG2a in murine models or engineered human IgG1 variants)

  • Fine-tuning Fc domains to balance therapeutic activity with on-target off-tumor toxicity

• Targeted delivery approaches:

  • Local administration of Fc-engineered anti-CD47 antibodies to promote tumor infiltration of macrophages and antigen-specific T cells while minimizing systemic exposure

  • Tumor-targeted bispecific antibodies that combine CD47 targeting with another tumor-specific antigen to enhance selectivity

• Affinity modulation:

  • Developing anti-CD47 antibodies with reduced binding affinity to minimize binding to normal cells while maintaining sufficient tumor targeting

  • Creating bispecific antibodies with intentionally reduced CD47-binding affinity to widen the therapeutic window

• Combination therapies:

  • Combining anti-CD47 antibodies with tumor-targeting antibodies to enhance tumor specificity

  • Pairing with immune checkpoint inhibitors to capitalize on synergistic effects between innate and adaptive immunity

• Novel formulations:

  • Developing antibody formats that preferentially activate in the tumor microenvironment

  • Creating antibody-drug conjugates that combine CD47 targeting with payload delivery

These approaches aim to enhance the tumor-specific activity of anti-CD47 antibodies while reducing their impact on normal CD47-expressing cells.

What are the implications of CD47's differential expression on regulatory T cells versus other T cell populations?

The differential expression of CD47 on regulatory T cells (Tregs) versus other T cell populations has several important implications for anti-CD47 therapy:

• Selective depletion potential: The significantly higher expression of CD47 on CD4+FOXP3+ Tregs compared to CD4+FOXP3- conventional T cells or CD8+ T cells creates an opportunity for preferential depletion of immunosuppressive Tregs. This selective depletion can be achieved using Fc-optimized anti-CD47 antibodies that engage activating FcγRs .

• Reshaping the tumor immune microenvironment: Depletion of Tregs through anti-CD47 therapy can fundamentally alter the immunosuppressive nature of the tumor microenvironment. Research shows that treatment with anti-CD47 antibodies with strong FcγR binding leads to a significant decrease in the percentage of tumor-infiltrating Tregs, shifting the ratio in favor of CD8+ effector T cells .

• Enhanced anti-tumor immunity: By depleting Tregs while relatively sparing CD8+ T cells, anti-CD47 antibodies with appropriate Fc domains can promote increased CD8+ T cell activation and infiltration into tumors. This enhanced CD8+ T cell response contributes to improved tumor control and the development of long-term anti-tumor immunity .

• Dual mechanism of action: The differential expression pattern suggests that anti-CD47 antibodies operate through at least two distinct mechanisms: blockade of the CD47-SIRPα "don't eat me" signal to enhance phagocytosis, and selective depletion of Tregs to reduce immunosuppression .

These implications highlight the importance of considering CD47's varied expression across immune cell populations when developing and optimizing anti-CD47 therapeutic strategies.

How can humanized mouse models be utilized to better predict clinical outcomes of anti-CD47 therapy?

Humanized mouse models offer significant advantages for predicting clinical outcomes of anti-CD47 therapy:

• Recapitulation of toxicity profiles: Mice humanized for CD47, SIRPα, and FcγRs can better recapitulate the on-target off-tumor toxicity observed in clinical settings, particularly anemia and thrombocytopenia. These models express human CD47 with comparable patterns to humans (ubiquitously on RBCs, platelets, CD3+ and CD11b+ cells) and human SIRPα primarily on CD11b+ cells .

• Evaluation of fully human antibodies: These models allow for direct testing of clinically relevant fully human anti-CD47 antibodies in an immunocompetent background, overcoming limitations of traditional xenograft or purely murine systems .

• Comparative testing of different Fc variants: Humanized models permit side-by-side comparison of different Fc variants of anti-CD47 antibodies (e.g., hIgG4 vs. enhanced FcγR binding variants) to assess both efficacy and toxicity profiles that more closely mirror human outcomes .

• Assessment of combination therapies: These models facilitate evaluation of clinically relevant combination strategies, such as pairing anti-CD47 antibodies with tumor-targeting antibodies or immune checkpoint inhibitors .

• Investigation of bispecific approaches: Humanized models enable testing of novel bispecific antibodies targeting human CD47 and other human immune checkpoints in an immune-intact environment .

Most importantly, these humanized models overcome the limitations of previously used models (xenograft, immunocompromised, or purely murine backgrounds) that failed to fully recapitulate both the toxicity and therapeutic activity observed in clinical trials .

What are the most promising combination strategies for anti-CD47 antibodies?

Based on current research, several promising combination strategies for anti-CD47 antibodies have emerged:

• Combination with tumor-targeting antibodies: Anti-CD47 antibodies combined with antibodies targeting tumor-specific antigens (like anti-gp75) show significantly enhanced efficacy compared to either agent alone. This approach leverages both the blockade of the "don't eat me" signal and the enhancement of "eat me" signals .

• Combination with immune checkpoint inhibitors: Pairing anti-CD47 antibodies with immune checkpoint inhibitors like anti-PD-1 antibodies significantly decreases tumor burden compared to checkpoint blockade alone. This strategy simultaneously targets both innate and adaptive immune responses .

• Bispecific antibody approaches: Novel bispecific antibodies targeting both CD47 and PD-1, such as HX009, represent a promising strategy that may improve both efficacy and safety profiles compared to combination therapy with separate antibodies .

• Fc-optimized combinations: Using anti-CD47 antibodies with Fc domains optimized for activating FcγR engagement (like mIgG2a in mouse models) in combination therapies shows superior efficacy compared to combinations using Fc variants with reduced FcγR binding .

These combination approaches address the limitations of anti-CD47 monotherapy by engaging multiple immune pathways and potentially enhancing tumor specificity.

What are the mechanisms behind on-target off-tumor toxicities of anti-CD47 antibodies?

The on-target off-tumor toxicities of anti-CD47 antibodies arise from several interconnected mechanisms:

• Ubiquitous expression pattern: CD47 is widely expressed on normal healthy cells throughout the body, including red blood cells (RBCs), platelets, and various leukocytes. This ubiquitous expression makes these cells potential targets for anti-CD47 antibodies .

• Fc-dependent mechanisms: The crystallizable fragment (Fc) of anti-CD47 antibodies can engage Fc gamma receptors (FcγRs) on immune cells, particularly those with phagocytic capacity. This engagement can trigger:

  • Antibody-dependent cellular phagocytosis (ADCP) of opsonized normal cells

  • Antibody-dependent cellular cytotoxicity (ADCC) against CD47-expressing normal cells

  • Complement-dependent cytotoxicity (CDC) depending on the antibody isotype

• SIRPα blockade effects: By blocking the CD47-SIRPα interaction, anti-CD47 antibodies remove the "don't eat me" signal that normally protects healthy cells from phagocytosis, potentially leading to increased clearance of normal cells, particularly aged or stressed cells that may display additional "eat me" signals .

• Differential toxicity by antibody format:

  • Antibodies with strong FcγR engagement (hIgG1 format) typically show higher levels of toxicity

  • Antibodies with weak or null FcγR engagement (hIgG4, hIgG2, or inert Fc) generally demonstrate better tolerability but reduced efficacy

Understanding these mechanisms has led to strategies to mitigate toxicity, including Fc engineering, affinity modulation, bispecific approaches, and priming dose strategies.